EVERSANA COMPLETE COMMERCIALIZATION
Greg Skalicky, Chief Revenue Officer
EVERSANA opened its doors in October of 2018 with the goal of becoming the first, truly integrated commercial organization to position therapies for success by breaking down traditional industry service silos and investing in technology, infrastructure, partnerships, and expanding global markets. The company built a disruptive, end-to-end commercialization solution for manufacturers to maximize the value of their products and increase efficiencies.
Until now, manufacturers traditionally had three options to consider when commercializing a product: sell, out-license the product, or build the infrastructure to commercialize on their own. EVERSANA offers an innovative fourth option: EVERSANA COMPLETE COMMERCIALIZATION. As a commercial partner, EVERSANA’s commercial platform enables manufacturers to release a product into their ecosystem for complete A-to-Z commercialization.
The model protects a manufacturer’s upfront investment by providing full-scale commercial strategy, operational excellence, and a success share delivery platform that de-risks financial barriers, helps to navigate any unexpected challenges during commercialization (FDA approvals, uncertain market conditions, compliance or operational issues), saves time, and allows them to keep the lion’s share of their products value.
Launched this year, EVERSANA COMPLETE COMMERCIALIZATION has already become a disruptive force leading the shift to patient-centered, value-based care and complete commercialization, partnering with clients at all aspects of product launch to ensure vital therapies reach patients. The company is working with Palette Life Sciences to support U.S. commercialization and distribution activities of Solesta, the only FDA-approved minimally invasive treatment for bowel incontinence; Evoke Pharma, Inc. to commercialize and distribute Gimoti, a nasal spray product candidate for women with acute and recurrent diabetic gastroparesis; and Zosano Pharma to commercialize and distribute Qtrypta, a first-of-its-kind transdermal microneedle therapy for the acute treatment of migraines.